Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.77
PFE's Cash to Debt is ranked lower than
66% of the 702 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.66 vs. PFE: 0.77 )
Ranked among companies with meaningful Cash to Debt only.
PFE' s 10-Year Cash to Debt Range
Min: 0.14  Med: 0.90 Max: 3.47
Current: 0.77
0.14
3.47
Equity to Asset 0.42
PFE's Equity to Asset is ranked lower than
78% of the 563 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.63 vs. PFE: 0.42 )
Ranked among companies with meaningful Equity to Asset only.
PFE' s 10-Year Equity to Asset Range
Min: 0.41  Med: 0.47 Max: 0.66
Current: 0.42
0.41
0.66
F-Score: 6
Z-Score: 2.87
M-Score: -2.67
WACC vs ROIC
2.36%
12.05%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 25.89
PFE's Operating margin (%) is ranked higher than
88% of the 660 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.81 vs. PFE: 25.89 )
Ranked among companies with meaningful Operating margin (%) only.
PFE' s 10-Year Operating margin (%) Range
Min: 9.51  Med: 24.15 Max: 35.89
Current: 25.89
9.51
35.89
Net-margin (%) 18.69
PFE's Net-margin (%) is ranked higher than
84% of the 661 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.92 vs. PFE: 18.69 )
Ranked among companies with meaningful Net-margin (%) only.
PFE' s 10-Year Net-margin (%) Range
Min: 8.74  Med: 18.26 Max: 42.65
Current: 18.69
8.74
42.65
ROE (%) 12.37
PFE's ROE (%) is ranked higher than
65% of the 685 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.31 vs. PFE: 12.37 )
Ranked among companies with meaningful ROE (%) only.
PFE' s 10-Year ROE (%) Range
Min: 9.16  Med: 17.83 Max: 55.34
Current: 12.37
9.16
55.34
ROA (%) 5.43
PFE's ROA (%) is ranked higher than
59% of the 706 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.19 vs. PFE: 5.43 )
Ranked among companies with meaningful ROA (%) only.
PFE' s 10-Year ROA (%) Range
Min: 4.05  Med: 9.47 Max: 27.83
Current: 5.43
4.05
27.83
ROC (Joel Greenblatt) (%) 65.20
PFE's ROC (Joel Greenblatt) (%) is ranked higher than
87% of the 704 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 12.13 vs. PFE: 65.20 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
PFE' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 20.28  Med: 60.69 Max: 95.19
Current: 65.2
20.28
95.19
Revenue Growth (3Y)(%) -3.40
PFE's Revenue Growth (3Y)(%) is ranked lower than
76% of the 540 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.80 vs. PFE: -3.40 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
PFE' s 10-Year Revenue Growth (3Y)(%) Range
Min: -3.8  Med: 6.20 Max: 19.1
Current: -3.4
-3.8
19.1
EBITDA Growth (3Y)(%) -2.40
PFE's EBITDA Growth (3Y)(%) is ranked lower than
63% of the 483 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.80 vs. PFE: -2.40 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
PFE' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -4.7  Med: 8.00 Max: 35.5
Current: -2.4
-4.7
35.5
EPS Growth (3Y)(%) 10.00
PFE's EPS Growth (3Y)(%) is ranked higher than
58% of the 452 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.20 vs. PFE: 10.00 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
PFE' s 10-Year EPS Growth (3Y)(%) Range
Min: -26.8  Med: 5.30 Max: 90.5
Current: 10
-26.8
90.5
» PFE's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2014

PFE Guru Trades in Q3 2014

Steven Cohen 450,000 sh (New)
Paul Tudor Jones 105,737 sh (+552.70%)
Jeremy Grantham 1,111,454 sh (+218.01%)
David Dreman 15,040 sh (+10.47%)
Diamond Hill Capital 10,195,767 sh (+8.71%)
John Keeley 97,339 sh (+8.35%)
RS Investment Management 2,437,555 sh (+3.96%)
Brian Rogers 12,737,115 sh (+3.66%)
Charles Brandes 6,257,090 sh (+2.99%)
James Barrow 62,170,881 sh (+2.76%)
Bill Frels 2,630,017 sh (+2.20%)
John Buckingham 67,724 sh (+1.69%)
Ken Fisher 31,702,495 sh (+0.70%)
Murray Stahl 63,028 sh (+0.11%)
Robert Bruce 452,000 sh (unchged)
Pioneer Investments 3,512,725 sh (unchged)
Prem Watsa 235,000 sh (unchged)
Louis Moore Bacon 600,000 sh (unchged)
Eric Mindich 1,500,000 sh (unchged)
Vanguard Health Care Fund 14,934,022 sh (unchged)
Jim Simons Sold Out
HOTCHKIS & WILEY Sold Out
Jeff Auxier 145,628 sh (-0.02%)
Ruane Cunniff 10,967 sh (-0.18%)
NWQ Managers 6,338,458 sh (-0.39%)
Dodge & Cox 47,604,980 sh (-2.65%)
Ronald Muhlenkamp 39,499 sh (-3.71%)
Manning & Napier Advisors, Inc 842,466 sh (-4.52%)
Kahn Brothers 1,985,161 sh (-6.56%)
Joel Greenblatt 1,622,092 sh (-6.85%)
Mario Gabelli 1,023,581 sh (-7.29%)
Ray Dalio 295,108 sh (-24.91%)
Michael Price 47,100 sh (-56.02%)
Louis Moore Bacon 50,000 sh (-77.79%)
First Eagle Investment 135,661 sh (-94.11%)
» More
Q4 2014

PFE Guru Trades in Q4 2014

Richard Pzena 2,170,568 sh (New)
Bestinfond 635,978 sh (New)
First Eagle Investment 5,272,943 sh (+3786.85%)
Louis Moore Bacon 550,000 sh (+1000.00%)
Paul Tudor Jones 385,500 sh (+264.58%)
Steven Cohen 1,211,300 sh (+169.18%)
Pioneer Investments 5,414,346 sh (+54.14%)
Vanguard Health Care Fund 19,395,622 sh (+29.88%)
RS Investment Management 2,719,255 sh (+11.56%)
Manning & Napier Advisors, Inc 883,569 sh (+4.88%)
Diamond Hill Capital 10,612,885 sh (+4.09%)
John Keeley 99,959 sh (+2.69%)
Murray Stahl 64,055 sh (+1.63%)
Bill Frels 2,657,601 sh (+1.05%)
James Barrow 62,760,163 sh (+0.95%)
Robert Bruce 455,332 sh (+0.74%)
Charles Brandes 6,272,097 sh (+0.24%)
NWQ Managers 6,349,377 sh (+0.17%)
Ruane Cunniff 10,967 sh (unchged)
Louis Moore Bacon 600,000 sh (unchged)
Prem Watsa 235,000 sh (unchged)
Eric Mindich 1,500,000 sh (unchged)
Brian Rogers 12,737,115 sh (unchged)
Michael Price Sold Out
John Buckingham 67,663 sh (-0.09%)
Jeff Auxier 144,678 sh (-0.65%)
Dodge & Cox 47,195,573 sh (-0.86%)
Ken Fisher 31,196,415 sh (-1.60%)
David Dreman 14,792 sh (-1.65%)
Ronald Muhlenkamp 38,409 sh (-2.76%)
Kahn Brothers 1,883,217 sh (-5.14%)
Mario Gabelli 951,583 sh (-7.03%)
Joel Greenblatt 1,420,948 sh (-12.40%)
Ray Dalio 211,208 sh (-28.43%)
Jeremy Grantham 33,931 sh (-96.95%)
» More
Q1 2015

PFE Guru Trades in Q1 2015

Signature Select Canadian Fund 219,000 sh (New)
Jim Simons 2,622,441 sh (New)
Paul Tudor Jones 1,138,585 sh (+195.35%)
David Dreman 25,202 sh (+70.38%)
Joel Greenblatt 1,972,788 sh (+38.84%)
John Buckingham 71,247 sh (+5.30%)
Pioneer Investments 5,671,904 sh (+4.76%)
Ken Fisher 31,208,271 sh (+0.04%)
Robert Bruce 455,332 sh (unchged)
Brian Rogers 12,737,115 sh (unchged)
Steven Cohen 5,000,000 sh (unchged)
Ruane Cunniff 10,967 sh (unchged)
Vanguard Health Care Fund 19,395,622 sh (unchged)
Ronald Muhlenkamp 38,409 sh (unchged)
Prem Watsa 235,000 sh (unchged)
NWQ Managers 163,400 sh (unchged)
Bestinfond Sold Out
Ray Dalio Sold Out
First Eagle Investment 5,266,820 sh (-0.12%)
Richard Pzena 2,159,618 sh (-0.50%)
Manning & Napier Advisors, Inc 876,319 sh (-0.82%)
Dodge & Cox 46,776,959 sh (-0.89%)
John Keeley 98,689 sh (-1.27%)
Diamond Hill Capital 10,432,351 sh (-1.70%)
Charles Brandes 6,123,536 sh (-2.37%)
Jeremy Grantham 33,095 sh (-2.46%)
Kahn Brothers 1,811,016 sh (-3.83%)
RS Investment Management 2,600,485 sh (-4.37%)
Murray Stahl 60,746 sh (-5.17%)
Mario Gabelli 896,431 sh (-5.80%)
NWQ Managers 5,927,532 sh (-6.64%)
Bill Frels 2,363,506 sh (-11.07%)
James Barrow 55,080,222 sh (-12.24%)
Jeff Auxier 76,147 sh (-47.37%)
Steven Cohen 450,000 sh (-62.85%)
Louis Moore Bacon 125,000 sh (-77.27%)
» More
Q2 2015

PFE Guru Trades in Q2 2015

Ken Fisher 31,816,749 sh (+1.95%)
Vanguard Health Care Fund 19,395,622 sh (unchged)
Brian Rogers 12,737,115 sh (unchged)
Kahn Brothers 1,774,875 sh (-2.00%)
Manning & Napier Advisors, Inc 793,722 sh (-9.43%)
» More
» Details

Insider Trades

Latest Guru Trades with PFE

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on Pfizer Inc

Diamond Hill Capital Comments on Pfizer Inc - Jul 25, 2014

Shares of pharmaceutical company Pfizer, Inc. (PFE) declined after multiple attempts to merge with UK competitor AstraZeneca ultimately failed.

From Diamond Hill Capital (Trades, Portfolio)'s Select Fund Second Quarter 2014 Commentary.

Check out Diamond Hill Capital latest stock trades

Donald Yacktman Comments on Pfizer - Sep 09, 2013

Pfizer (NYSE:PFE) was removed from the funds due to price appreciation. The company has struggled to grow over time as it has not has not been able to produce enough new drug revenues to offset major patent expirations like Lipitor. Despite the lack of growth, the stock has appreciated significantly, and we do not think it represents a good value at current prices.

From Yacktman Funds' second quarter 2013 commentary.
Check out Donald Yacktman latest stock trades

Top Ranked Articles about Pfizer Inc

Richard Pzena's New Buys
Wharton School cum laude and Founder and Co-Chief Investment Officer of Pzena Investment Management LLC Richard Pzena (Trades, Portfolio) believes in investing in good businesses – but only when they go on sale. Read more...
Guru Stocks at 52-Week Lows: PFE, GSK, VOD, EC, MFG
According to GuruFocus list of 52-week lows, these Guru stocks have reached their 52-week lows. Read more...
Legendary Investor Irving Kahn's Top Five Stocks
One of America’s oldest and most respected value investors, Irving Kahn (Trades, Portfolio), and his fund Kahn Brothers recently reported their fourth quarter holdings which boasted several hefty reductions and one sell out. Over the past quarter Kahn added one new stock, and the guru now maintains 43 stocks valued at $687 million.
Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 25.00
PFE's P/E(ttm) is ranked higher than
66% of the 474 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 34.20 vs. PFE: 25.00 )
Ranked among companies with meaningful P/E(ttm) only.
PFE' s 10-Year P/E(ttm) Range
Min: 7.67  Med: 16.08 Max: 27.17
Current: 25
7.67
27.17
Forward P/E 14.81
PFE's Forward P/E is ranked higher than
78% of the 232 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 24.27 vs. PFE: 14.81 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 24.90
PFE's PE(NRI) is ranked higher than
66% of the 475 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 34.00 vs. PFE: 24.90 )
Ranked among companies with meaningful PE(NRI) only.
PFE' s 10-Year PE(NRI) Range
Min: 9.77  Med: 18.81 Max: 27.35
Current: 24.9
9.77
27.35
P/B 3.28
PFE's P/B is ranked higher than
52% of the 665 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.42 vs. PFE: 3.28 )
Ranked among companies with meaningful P/B only.
PFE' s 10-Year P/B Range
Min: 1.32  Med: 2.40 Max: 3.6
Current: 3.28
1.32
3.6
P/S 4.68
PFE's P/S is ranked lower than
62% of the 653 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.30 vs. PFE: 4.68 )
Ranked among companies with meaningful P/S only.
PFE' s 10-Year P/S Range
Min: 1.72  Med: 3.48 Max: 4.82
Current: 4.68
1.72
4.82
PFCF 17.68
PFE's PFCF is ranked higher than
84% of the 273 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 42.64 vs. PFE: 17.68 )
Ranked among companies with meaningful PFCF only.
PFE' s 10-Year PFCF Range
Min: 5.02  Med: 12.77 Max: 20.09
Current: 17.68
5.02
20.09
POCF 15.75
PFE's POCF is ranked higher than
75% of the 385 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 28.53 vs. PFE: 15.75 )
Ranked among companies with meaningful POCF only.
PFE' s 10-Year POCF Range
Min: 4.56  Med: 11.35 Max: 16.87
Current: 15.75
4.56
16.87
EV-to-EBIT 18.20
PFE's EV-to-EBIT is ranked higher than
64% of the 489 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 26.18 vs. PFE: 18.20 )
Ranked among companies with meaningful EV-to-EBIT only.
PFE' s 10-Year EV-to-EBIT Range
Min: 7.9  Med: 14.70 Max: 23.5
Current: 18.2
7.9
23.5
PEG 4.98
PFE's PEG is ranked lower than
66% of the 249 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.74 vs. PFE: 4.98 )
Ranked among companies with meaningful PEG only.
PFE' s 10-Year PEG Range
Min: 1.14  Med: 2.12 Max: 17.69
Current: 4.98
1.14
17.69
Shiller P/E 20.62
PFE's Shiller P/E is ranked higher than
77% of the 309 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 36.46 vs. PFE: 20.62 )
Ranked among companies with meaningful Shiller P/E only.
PFE' s 10-Year Shiller P/E Range
Min: 8.55  Med: 16.49 Max: 30.71
Current: 20.62
8.55
30.71
Current Ratio 2.45
PFE's Current Ratio is ranked higher than
54% of the 607 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.27 vs. PFE: 2.45 )
Ranked among companies with meaningful Current Ratio only.
PFE' s 10-Year Current Ratio Range
Min: 1.06  Med: 1.64 Max: 3.18
Current: 2.45
1.06
3.18
Quick Ratio 2.16
PFE's Quick Ratio is ranked higher than
60% of the 606 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.66 vs. PFE: 2.16 )
Ranked among companies with meaningful Quick Ratio only.
PFE' s 10-Year Quick Ratio Range
Min: 0.83  Med: 1.39 Max: 2.86
Current: 2.16
0.83
2.86
Days Inventory 234.66
PFE's Days Inventory is ranked lower than
88% of the 623 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 113.56 vs. PFE: 234.66 )
Ranked among companies with meaningful Days Inventory only.
PFE' s 10-Year Days Inventory Range
Min: 142.41  Med: 234.74 Max: 412.93
Current: 234.66
142.41
412.93
Days Sales Outstanding 66.29
PFE's Days Sales Outstanding is ranked higher than
54% of the 594 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 72.45 vs. PFE: 66.29 )
Ranked among companies with meaningful Days Sales Outstanding only.
PFE' s 10-Year Days Sales Outstanding Range
Min: 45.78  Med: 70.67 Max: 106.89
Current: 66.29
45.78
106.89

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 3.00
PFE's Dividend Yield is ranked higher than
86% of the 643 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.35 vs. PFE: 3.00 )
Ranked among companies with meaningful Dividend Yield only.
PFE' s 10-Year Dividend Yield Range
Min: 1.87  Med: 3.63 Max: 10.4
Current: 3
1.87
10.4
Dividend Payout 0.73
PFE's Dividend Payout is ranked higher than
82% of the 391 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.32 vs. PFE: 0.73 )
Ranked among companies with meaningful Dividend Payout only.
PFE' s 10-Year Dividend Payout Range
Min: 0.12  Med: 0.48 Max: 8.21
Current: 0.73
0.12
8.21
Dividend growth (3y) 9.10
PFE's Dividend growth (3y) is ranked higher than
56% of the 253 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.70 vs. PFE: 9.10 )
Ranked among companies with meaningful Dividend growth (3y) only.
PFE' s 10-Year Dividend growth (3y) Range
Min: -14.7  Med: 13.50 Max: 22.6
Current: 9.1
-14.7
22.6
Yield on cost (5-Year) 4.15
PFE's Yield on cost (5-Year) is ranked higher than
87% of the 646 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.50 vs. PFE: 4.15 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
PFE' s 10-Year Yield on cost (5-Year) Range
Min: 2.59  Med: 5.02 Max: 14.38
Current: 4.15
2.59
14.38
Share Buyback Rate 6.50
PFE's Share Buyback Rate is ranked higher than
99% of the 461 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -3.00 vs. PFE: 6.50 )
Ranked among companies with meaningful Share Buyback Rate only.
PFE' s 10-Year Share Buyback Rate Range
Min: 6.5  Med: -2.10 Max: -19
Current: 6.5

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 1.16
PFE's Price/Projected FCF is ranked higher than
87% of the 297 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.37 vs. PFE: 1.16 )
Ranked among companies with meaningful Price/Projected FCF only.
PFE' s 10-Year Price/Projected FCF Range
Min: 0.53  Med: 1.05 Max: 8.57
Current: 1.16
0.53
8.57
Price/Median PS Value 1.35
PFE's Price/Median PS Value is ranked higher than
51% of the 560 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.36 vs. PFE: 1.35 )
Ranked among companies with meaningful Price/Median PS Value only.
PFE' s 10-Year Price/Median PS Value Range
Min: 0.51  Med: 1.20 Max: 3.68
Current: 1.35
0.51
3.68
Price/Peter Lynch Fair Value 3.59
PFE's Price/Peter Lynch Fair Value is ranked lower than
79% of the 145 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.01 vs. PFE: 3.59 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
PFE' s 10-Year Price/Peter Lynch Fair Value Range
Min: 1.17  Med: 2.20 Max: 37.29
Current: 3.59
1.17
37.29
Earnings Yield (Greenblatt) (%) 5.50
PFE's Earnings Yield (Greenblatt) (%) is ranked higher than
75% of the 689 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.30 vs. PFE: 5.50 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
PFE' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 4.3  Med: 6.80 Max: 12.6
Current: 5.5
4.3
12.6
Forward Rate of Return (Yacktman) (%) 13.25
PFE's Forward Rate of Return (Yacktman) (%) is ranked higher than
65% of the 305 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.15 vs. PFE: 13.25 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
PFE' s 10-Year Forward Rate of Return (Yacktman) (%) Range
Min: 8.2  Med: 14.60 Max: 21
Current: 13.25
8.2
21

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare:GSK, JNJ, RHHBY, NVS, ABT » details
Traded in other countries:PFZ.UK, PFEBC.Belgium, PFE.Sweden, PFE.Switzerland, PFE.Germany, PFE.Chile, PFE.Mexico, PFE.Argentina, PFIZ34.Brazil,
Pfizer Inc was incorporated under the laws of the State of Delaware on June 2, 1942. It is a research-based, biopharmaceutical company. The Company applies science and its resources to bring therapies to people that extend and improve their lives through the discovery, development and manufacture of healthcare products. The Company's portfolio includes medicines and vaccines, as well as many of the world's known consumer healthcare products. The Company managed its operations through four operating segments-Primary Care; Specialty Care and Oncology; Established Products and Emerging Markets; and Consumer Healthcare. Primary Care operating segment-included revenues from prescription pharmaceutical products prescribed by primary-care physicians, and included products in the following therapeutic and disease areas: Alzheimer's disease, cardiovascular (excluding pulmonary arterial hypertension) erectile dysfunction, and genitourinary, depressive disorder, and pain, respiratory and smoking cessation. Specialty Care and Oncology operating segment-was comprised of the Specialty Care business unit and the Oncology business unit. Established Products segment included revenues from prescription pharmaceutical products that had lost patent protection or marketing exclusivity in certain countries and/or regions. Emerging Markets-included revenues from all prescription pharmaceutical products sold in emerging markets, including Asia excluding Japan and South Korea, Latin America, the Middle East, Eastern Europe, Africa, Turkey and Central Europe. Consumer Healthcare operating segment-includes revenues from non-prescription products in the following therapeutic categories: dietary supplements, pain management, respiratory and personal care. In 2013, products marketed by Consumer Healthcare included Advil, Caltrate, Centrum, ChapStick, Emergen-C, Preparation H and Robitussin. In its biopharmaceutical businesses, the Company promotes its products to healthcare providers and patients. The Company also markets directly to consumers in the U.S. through direct-to-consumer advertising that communicates the approved uses, benefits and risks of its products while motivating people to have meaningful conversations with their doctors. Its biotechnology products, including BeneFIX, ReFacto, Xyntha, Enbrel and the Prevnar family, may face competition in the future from biosimilars. The Company competes with other companies that manufacture and sell products that treat diseases or indications similar to those treated by its products. The Company is subject to regulation by national, state and local agencies in the countries in which it does business.
» More Articles for PFE

Headlines

Articles On GuruFocus.com
Pfizer Increases Annual Earnings Guidance for 2015 Jul 29 2015 
It’s Not Too Late To Buy Gilead Sciences Jul 17 2015 
Perrigo Company Is Strong But Overvalued Jul 15 2015 
Despite Recent Downgrade, This Ecommerce Giant is a Buy Jun 29 2015 
Paul Tudor Jones' Top Three Stocks Deliver Positive Returns Jun 24 2015 
Bristol-Myers Squibb Takes A Step Up On Cancer Drugs, But The Cost Tells A Different Story Jun 22 2015 
A Look at James Barrow's Investment in Pfizer Jun 16 2015 
Jim Simons' Top 3 Positions and One That Doubled Return Jun 10 2015 
Will GlaxoSmithKline Cut Its 6% Dividend? Jun 03 2015 
Apple, SunEdison and Biogen: Hellman, Jordan Management's Top 3 Stocks Outperform the Rise in the S& May 28 2015 

More From Other Websites
Citing hacking risk, FDA says Hospira pump shouldn't be used Jul 31 2015
FDA says hospitals should stop using Hospira pump Jul 31 2015
FDA says hospitals should stop using Hospira pump Jul 31 2015
Top Drug Stock Pfizer In Buy Area After Earnings Beat Jul 31 2015
Your first trade for Monday, August 3 Jul 31 2015
Fast Money Final Trade: XOM, Z, GDX & PFE Jul 31 2015
PFIZER INC Financials Jul 31 2015
Roche drug maker probed in Romanian graft case Jul 31 2015
Roche drug maker probed in Romanian graft case Jul 31 2015
Dow 30 Stock Roundup: Pfizer, P&G, Merck Beat on Earnings, DuPont Misses Estimates - Analyst Blog Jul 31 2015
Stocks Open Mixed, Dow Lags; Expedia, Amgen, NewLink Rising Jul 31 2015
S&P 500 Index Futures Mixed In Choppy Session Jul 31 2015
4 Merrill Lynch Big, Old and Ugly Stocks To Buy For The Rest Of 2015 Jul 31 2015
Bull Chart of the Day -- Pfizer Remains Healthy Jul 29 2015
Big Pharma seeks recreational drug users for clinical trials Jul 29 2015
Dow adds 100 points as Street awaits Fed statement; earnings eyed Jul 29 2015
Pfizer Pulls The Plug On OTC Lipitor And It's The Patients' Fault Jul 29 2015
Top 10 New Stocks to Trade Like Hedge Fund Renaissance Technologies Jul 29 2015
Hospira Reports Second-Quarter 2015 Results Jul 29 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK